To assess the therapeutic utility of AAVHSC15 and AAVHSC17, two recently described Clade F adeno-associated viruses (AAVs), the seroprevalence of neutralizing antibodies (NAbs) to these AAVs was assessed in a representative human population and compared to that of AAV9. NAb levels were measured in 100 unique human sera of different races (34, Black, 33 Caucasian, and 33 Hispanic) and sex (49% female, 51% male) collected within the United States. Fifty-six sera were tested in Huh7 cells and 44 sera were tested in 2V6.11 cells with vectors packaged with either a CMV-promoter upstream of LacZ or a CBA-promoter upstream of Firefly Luciferase, respectively. For AAVHSC15, AAVHSC17, and AAV9, 24/100 (24%), 21/100 (21%), and 17/100 (17%), respectively, of all sera tested were seropositive for NAbs using 50% inhibition of cellular transduction at a 1/16 dilution of serum as cutoff for seropositivity. Only 6% of positive sera had titers of 1/150 to 1/340, indicating that the majority of positive sera were of low titer. Significant cross-reactivity of NAbs across all three AAV serotypes was observed. These data show that approximately 80% of humans evaluated were seronegative for pre-existing NAbs to the AAV serotypes tested, suggesting that the vast majority of human subjects would be amenable to therapeutic intervention with Clade F AAVs.
CalcedoR, VandenbergheLH, GaoG, et al.Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis, 2009; 199:381–390.
5.
CalcedoR, MorizonoH, WangL, et al.Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol, 2011; 18:1586–1588.
6.
GaoG, VandenbergheLH, AlviraMR, et al.Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol, 2004; 78:6381–6388.
7.
BlacklowNR, HogganMD, RoweWP. Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst, 1968; 40:319–327.
8.
RaptiK, Louis-JeuneV, KohlbrennerE, et al.Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther, 2012; 20:73–83.
GaoG, AlviraMR, SomanathanS, et al.Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A, 2003; 100:6081–6086.
11.
HurlbutGD, ZieglerRJ, NietupskiJB, et al.Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol Ther, 2010; 18:1983–1994.
12.
WangL, CalcedoR, WangH, et al.The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther, 2010; 18:126–134.
13.
ScallanCD, JiangH, LiuT, et al.Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood, 2006; 107:1810–1817.
14.
MingozziF, HighKA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 2013; 122:23–36.
15.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
16.
ThwaiteR, PagesG, ChillonM, et al.AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy. Gene Ther, 2015; 22:196–201.
17.
BoutinS, MonteilhetV, VeronP, et al.Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther, 2010; 21:704–712.
18.
WangM, CrosbyA, HastieE, et al.Prediction of adeno-associated virus neutralizing antibody activity for clinical application. Gene Ther, 2015; 22:984–992.
19.
SmithLJ, Ul-HasanT, CarvainesSK, et al.Gene transfer properties and structural modeling of human stem cell-derived AAV. Mol Ther, 2014; 22:1625–1634.
20.
GaoG, Sena-EstevesM. Introducing genes into mammalian cells: viral vectors. In: GreenM, SambrookJ, eds. Molecular Cloning, A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Press, 2012:1209–1313.
21.
MelianiA, LeborgneC, TriffaultS, et al.Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum Gene Ther Methods, 2015; 26:45–53.
22.
BernsKI, MuzyczkaN. AAV: an overview of unanswered questions. Hum Gene Ther, 2017; 28:308–313.
23.
DaytonRD, WangDB, KleinRL. The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther, 2012; 12:757–766.
24.
MaguireAM, SimonelliF, PierceEA, et al.Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med, 2008; 358:2240–2248.
25.
SimonelliF, MaguireAM, TestaF, et al.Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther, 2010; 18:643–650.
26.
KotcheyNM, AdachiK, ZahidM, et al.A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol Ther, 2011; 19:1079–1089.
27.
van GestelMA, BoenderAJ, de VrindVA, et al.Recombinant adeno-associated virus: efficient transduction of the rat VMH and clearance from blood. PLoS One, 2014; 9:e97639.
28.
ZincarelliC, SoltysS, RengoG, et al.Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther, 2008; 16:1073–1080.
29.
GreigJA, NordinJM, BoteE, et al.Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques. Mol Ther Methods Clin Dev, 2016; 3:16079.
30.
MimuroJ, MizukamiH, HishikawaS, et al.Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol Ther, 2013; 21:318–323.
31.
JiangH, CoutoLB, Patarroyo-WhiteS, et al.Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood, 2006; 108:3321–3328.
32.
McIntoshJH, CochraneM, CobboldS, et al.Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther, 2012; 19:78–85.
33.
GernouxG, WilsonJM, MuellerC. Regulatory and exhausted T cell responses to AAV capsid. Hum Gene Ther, 2017; 28:338–349.
34.
MingozziF, ChenY, MurphySL, et al.Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther, 2012; 20:1410–1416.
35.
ChicoineLG, MontgomeryCL, BremerWG, et al.Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther, 2014; 22:338–347.
